News: CTX cells for Critical Limb Ischaemia

In this interview, CFO Michael Hunt explains the core technology of ReNeuron’s business, the stem cell science it is developing, optimising and harnessing to create therapeutic products. He discusses the recently reported early Phase II clinical trial data for its CTX stem cell therapy in stroke and why this has given ReNeuron the confidence to commence a pivotal Phase II/III clinical trial in 2017. Finally, he also discusses expected newsflow resulting from the remainder of ReNeuron’s pipeline – critical limb ischaemia (Phase I) and hRPC or retinitis pigmentosa (Phase I/II).

For the interview please click here…

 

 

Guildford, UK, 27 March 2014: ReNeuron Group plc (the “Company”) (AIM: RENE.L), a leading UK-based stem cell therapy company, is pleased to announce that it has received final UK regulatory and ethical approvals to commence two new clinical trials

Read More …. 

Guildford, UK, 26 March 2013:  ReNeuron is pleased to announce that it has received regulatory and ethical approvals to commence a Phase I clinical trial in the UK with its ReN009 stem cell therapy programme targeting the major unmet medical need, critical limb ischaemia (CLI).

More…